TYPE 2 MYOCARDIAL INFARCTION: MODERN DIAGNOSTIC TECHNIQUES AND TREATMENT

Highlights

Patients with type 2 myocardial infarction have a more favorable course of the disease in the long-term postinfarction period compared with patients with type 1 myocardial infarction. We have determined the differences in clinical and anamnestic characteristics of patients with type 1 and type 2 MI.

Abstract

Aim. To determine the prevalence of patients with type 2 myocardial infarction (MI) and their features in clinical practice.

Methods. The prospective study involved 204 patients with acute coronary syndrome (ACS). The inclusion criteria were as follows: diagnosed ACS at admission followed by a confirmed MI during the inpatient period according to the Fourth Universal definition of MI. The following parameters were analyzed: anthropometric parameters, clinical and anamnestic characteristics, results of laboratory tests, biochemical markers of myocardial necrosis, results of instrumental diagnostics and coronary angiography. A follow-up telephone survey was carried out a year after ACS, noting the following endpoints: repeated coronary events, death, repeated hospitalizations, adherence to medical recommendations, medication taken by the patient.

Results. Type 2 MI was diagnosed in 22 (10.8%) patients. The results of coronary angiography revealed either the absence of coronary artery (CA) stenosis or the presence of stenosis of less than 50% without indications of thrombosis in 16 (72.7%) of those patients. Chronic total occlusion of a non-infarct-related artery was found in 6 (27.3%) patients. Patients with type 2 MI were comparable in age with patients with type 1 MI. The group of patients with type 2 MI included more women (p = 0.029), fewer smokers (p = 0.037) and more cases of atrial fibrillation (AF) (p = 0.003) compared to patients with type 1 MI. The factors that were associated with type 2 MI were as follows: sinus tachycardia in 3 (13.6%) patients, paroxysmal atrial flutter or AF with ventricular tachysystole in 4 patients (18.2%).

Conclusion. Patients with type 1 MI presented with a less favorable course of the disease: we noted higher number of recurrent MI and deaths one year after the index event compared with patients with type 2 MI. The group of patients with type 2 MI consisted mostly of women, fewer smokers and patients with dyslipidemia, as well as a more frequent indication of AF compared with patients with type 1 MI.

1. Thygesen K., Alpert J.S., Jaffe A.S.., Chaitman B.R., Bax J.J., Morrow D.A., White H.D; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction.Fourth universal definition of myocardial infarction. 2018. Circulation. 2018;138(20):618-651. doi: 10.1161/CIR.0000000000000617

2. Collinson P., Lindahl B. Type 2 Myocardial Infarction: The Chimaera of Cardiology? Heart. 2015; 101(21): 1697-1703. doi: 10.1136/heartjnl-2014-307122

3. Hawatmeh A., Thawabi M., Aggarwal R., Abirami C., Vavilin I., Wasty N., Visveswaran G., Cohen M. Implications of Misclassification of Type 2 Myocardial Infarction on Clinical Outcomes. Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2020;21(2):176-179. doi: 10.1016/j.carrev.2019.04.009.

4. McCarthy C.P., Kolte D., Kennedy K.F., Pandey A., Raber I., Oseran A., Wadhera R.K., Vaduganathan M., Januzzi J.L.Jr., Wasfy J.H. Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. J Am Coll Cardiol. 2021;78(12):1242-1253. doi: 10.1016/j.jacc.2021.07.034

5. Аверков О.В., Барбараш О.Л., Бойцов С.А., Васильева Е.Ю., Драпкина О.М., Галявич А.С., Гиляров М.Ю., Зайратьянц О.В., Кактурский Л.В., Карпов Ю.А., Мишнев О.Д., Никулина Н.Н., Орехов О.О., Самородская И.В., Соболева Г.Н., Черкасов С.Н., Шахнович Р.М., Шилова А.С., Шляхто Е.В., Шпектор А.В., Явелов И.С., Якушин С.С.Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа. Российский кардиологический журнал. 2019; 24(6): 7-21. doi: 10.15829/1560-4071-2019-6-7-21

6. Baron T., Hambraeus K., Sundstrom J., Erlinge D., Jernberg T., Lindahl B.; TOTALAMI study group. Type 2 myocardial infarction in clinical practice. Heart. 2015; 101: 101–106. doi: 10.1136/heartjnl-2014-306093.

7. Tamis-Holland J.E., Jneid H., Reynolds H.R., Agewall S., Brilakis E.S., Brown T.M., Lerman A., Cushman M., Kumbhani D.J., Arslanian-Engoren C., Bolger A.F., Beltrame J.F.; American Heart Association Interventional Cardiovascular Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):891-908. doi: 10.1161/CIR.0000000000000670.

8. Szymański F.M., Karpiński G., Płatek A.E., Majstrak F., Hrynkiewicz-Szymańska A., Kotkowski M., Puchalski B., Filipiak K.J., Opolski G. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiologia Polska. 2014; 72(4): 339–344. doi: 10.5603/kp.a2013.0284

9. Жарский С.Л. Инфаркт миокарда второго типа: современное состояние проблемы. Дальневосточный медицинский журнал, 2016;3: 134-138. doi: 10.1161/circulationaha.108.828228

10. Saaby L., Poulsen TS., Hosbond S., Larsen TB., Pyndt Diederichsen AC., Hallas J., Thygesen K., Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. The American Journal of Medicine. 2013;126(9):789–97. doi: 10.1016/j.amjmed.2013.02.029.

11. Musher D.M., Abers M.S., Corrales-Medina V.F. Acute infection and myocardial infarction. N. Engl. J. Med. 2019; 380 (2): 171-176. doi: 10.1056/NEJMra1808137

12. Chapman A.R., Shah A.S.V., Lee K.K. Long term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation.2018; 137: 1236–45. doi: 10.1161/CIRCULATIONAHA.117.031806.

13. Guimarães P. O., Leonardi S., Huang Z., Wallentin L., Van de Werf F., Aylward P. E., Held C., Harrington R.A., Moliterno D.J., Armstrong P.W., White H.D., Alexander K.P., Lopes R.D., Mahaffey K.W., Tricoci P. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. American Heart Journal. 2018; 196: 28-35. doi: 10.1016/j.ahj.2017.10.007

14. Raphael C.E., Roger V.L., Sandoval Y., Johnson M., Jaffe A., Lerman A., Rihal C.S., Bell M.R., Singh M., Gulati R. Causes of Death After Type 2 Myocardial Infarction and Myocardial Injury. J Am Coll Cardiol. 2021;78(4):415-416. doi: 10.1016/j.jacc.2021.05.026.